AIM ImmunoTech (AIM) vs Bolt Biotherapeutics (BOLT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Bolt Biotherapeutics is the larger company by market cap ($7.9 million vs $7.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AIM | BOLT |
|---|---|---|
| Share price | $0.18 | $4.11 |
| Market cap | $7.18M | $7.92M |
| 1-day change | +0.22% | +13.22% |
| EPS (TTM) | $-2.98 | $-16.51 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.79 | $7.20 |
| 52-week low | $0.17 | $3.10 |
| Distance from 52-week high | -93.56% | -42.92% |
| Analyst consensus | none | none |
| Avg. price target upside | +2261.11% | +605.60% |
| Average volume | 4.70M | 26.26K |
| Shares outstanding | 39.89M | 1.93M |
| Employees | 19 | 23 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About AIM ImmunoTech
AIM stock →AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 19 employees
About Bolt Biotherapeutics
BOLT stock →Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company's pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small cell lung cancer, melanoma, and other solid tumors; CEA ISAC, a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 for the treatment of solid tumors, including colorectal, non-small cell lung, pancreatic, and breast; and PD-L1 ISAC, a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker to target both tumor and immune cells for the treatment of tumor regression and immunological memory.
Health Care · Biotechnology: Pharmaceutical Preparations · 23 employees
AIM vs BOLT FAQ
Which is bigger, AIM ImmunoTech or Bolt Biotherapeutics?
Bolt Biotherapeutics (BOLT) is larger, with a market capitalization of $7.92M compared with $7.18M for AIM ImmunoTech (AIM).
Are AIM ImmunoTech and Bolt Biotherapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for AIM ImmunoTech and Biotechnology: Pharmaceutical Preparations for Bolt Biotherapeutics.